Abstract
The scientific information about melanoma is on the rise. It has a direct impact on the diagnostic acuteness and on the therapeutic management. The most recent aspects of the utmost importance are presented. The concept of the duality between fast-growing (high malignancy) and slow-growing (reduced malignancy) melanoma is stressed. A new international multicentric approach using adjuvant therapy for stage III melanomas involves the clinical oncology department of the CHU of Liège. It concerns a targeted immunotherapy directed to the Mage A3 protein.
MeSH terms
-
Antigens, Neoplasm / metabolism
-
Biomarkers, Tumor / metabolism
-
Humans
-
Immunologic Factors / administration & dosage
-
Immunotherapy
-
Injections, Intravenous
-
Interferon-alpha / administration & dosage
-
Melanoma / diagnosis
-
Melanoma / metabolism
-
Melanoma / pathology*
-
Melanoma / therapy*
-
Neoplasm Proteins / metabolism
-
Prognosis
-
Sentinel Lymph Node Biopsy*
-
Skin Neoplasms / diagnosis
-
Skin Neoplasms / metabolism
-
Skin Neoplasms / pathology*
-
Skin Neoplasms / therapy*
-
Treatment Outcome
Substances
-
Antigens, Neoplasm
-
Biomarkers, Tumor
-
Immunologic Factors
-
Interferon-alpha
-
MAGEA3 protein, human
-
Neoplasm Proteins